According to the literature review, treatment with [177Lu]Lu-PSMA has a positive impact on prostate-specific antigen (PSA) within the first cycle and a negative impact on lymph node metastasis. The gene discussed is FOLH1; the disease is metastatic malignant neoplasm in the lymph nodes.